Alexion Pharmaceuticals has reached a national funding agreement with the National Institute for Health and Care Excellence and the National Health Service England based on a Managed Access Agreement, which provides access to Strensiq® (asfotase alfa) for patients in England with pediatric-onset hypophosphatasia, regardless of their current age​ … more

Separately, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to extend the current therapeutic indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis in patients who are anti-acetylcholine receptor antibody-positive. The final decision from the European Commission is anticipated in the third quarter of 2017… more